Heron Therapeutics(HRTX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance • Reported positive YTD 2024 Adjusted EBITDA of $1.4 million • Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million • ZYNRELEF ®(bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launch • CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment ...